Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11345925 | 0.85 | LMNA (0.34) | ALDH1A1ALOX15TSHRLMNAKDM4E | |
| SCHEMBL11350854 | 0.83 | LMNA (0.33) | ALDH1A1ALOX15TSHRLMNAKDM4E | |
| SCHEMBL5674047 | 0.83 | KDM4E (0.37) | ALDH1A1ALOX15TSHRLMNAKDM4E | |
| SCHEMBL22024694 | 0.83 | LMNA (0.41) | ALDH1A1ALOX15TSHRLMNAKDM4E | |
| SCHEMBL31627684 | 0.83 | KDM4E (0.37) | ALDH1A1ALOX15TSHRLMNAKDM4E | |
| SCHEMBL29950870 | 0.83 | LMNA (0.41) | ALDH1A1ALOX15TSHRLMNAKDM4E | |
| SCHEMBL192661 | 0.80 | LMNA (0.55) | ALDH1A1LMNAKDM4EMAPTNPSR1 | |
| SCHEMBL6066162 | 0.78 | LMNA (0.36) | ALDH1A1LMNAKDM4EMAPTNPSR1 | |
| SCHEMBL11338618 | 0.78 | LMNA (0.36) | ALDH1A1LMNAKDM4EMAPTNPSR1 | |
| SCHEMBL114532 | 0.78 | MAPT (0.40) | ALDH1A1LMNAKDM4EMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 733 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115368367-B | Pyrimidinone derivative and preparation method and application thereof | 中山大学 | 2023-10-31 | — | — | CN | claimed |
| CN-115368367-A | Pyrimidone derivative and preparation method and application thereof | 中山大学 | 2022-11-22 | — | — | CN | claimed |
| CN-110078736-B | Pyrazolopyrimidine derivative, process for producing the same, and use thereof | 广州白云山医药集团股份有限公司白云山制药总厂 | 2021-08-03 | — | — | CN | claimed |
| CN-110862394-A | Preparation method of PDE9A inhibitor | 广州白云山医药集团股份有限公司白云山制药总厂 | 2020-03-06 | — | — | CN | claimed |
| CN-110078736-A | Pyrazolopyrimidine derivative, preparation method and its application | 广州白云山医药集团股份有限公司白云山制药总厂 | 2019-08-02 | — | — | CN | claimed |
| US-9617269-B2 | N-substituted pyrazolo [3,4-D] pyrimidine ketone compound, and preparation process and use thereof | SUN YAT-SEN UNIVERSITY (CN) | 2017-04-11 | — | — | US | claimed |
| US-20150218168-A1 | N-SUBSTITUTED PYRAZOLO [3,4-D] PYRIMIDINE KETONE COMPOUND, AND PREPARATION PROCESS AND USE THEREOF | SUN YAT-SEN UNIVERSITY (CN) | 2015-08-06 | — | — | US | claimed |
| EP-1893585-A1 | PROCESS FOR THE PREPARATION OF N-[4-(4-FLUOROPHENYL)-5-FORMYL-6-ISOPROPYL-PYRIMIDIN-2-YL]-N-METHYLMETHANESULFONAMIDE | Fermion Oy (FI) | 2008-03-05 | — | — | EP | claimed |
| WO-2006128954-A1 | PROCESS FOR THE PREPARATION OF N-[4-(4-FLUOROPHENYL)-5-FORMYL-6-ISOPROPYL-PYRIMIDIN-2-YL]-N-METHYLMETHANESULFONAMIDE | FERMION OY (FI) | 2006-12-07 | — | — | WO | claimed |
| JP-59005186-A | — | — | None | — | — | JP | disclosed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4746963-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743465-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4739670-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-4126609-A | AZO DYESTUFF WITH A FIBER-REACTIVE GROUP ATTACHED TO A NAPHTHALENE SULPHONIC ACID COMPONENT | BAYER AKTIENGESELLSCHAFT (DE) | 1978-11-21 | — | — | US | disclosed |
| US-4089895-A | COUPLER FOR AZO DYES | BAYER AKTIENGESELLSCHAFT (DT) | 1978-05-16 | — | — | US | disclosed |
| US-4065446-A | Reactive dyestuffs containing urea alkylene linkage between chromophore and reactive radical | BAYER AKTIENGESELLSCHAFT (DT) | 1977-12-27 | — | — | US | disclosed |
| US-4049704-A | AZO REACTIVE DYES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-20 | — | — | US | disclosed |
| US-3989692-A | PHTHALOCYANINE DYES, WOOL, SILK, POLYAMIDES, CELLULOSE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
| US-3957751-A | WATER-SOLUBLE REACTIVE DYESTUFFS OF THE MONOAZO SERIES CONTAINING AN ACTIVE METHYLENE COUPLING COMPONENT | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218168-A1 | N-SUBSTITUTED PYRAZOLO [3,4-D] PYRIMIDINE KETONE COMPOUND, AND PREPARATION PROCESS AND USE THEREOF | PDE3B, PDE3A, PDE2A | ALDH1A1 581/4885ALOX15 4280/4885TSHR 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.